Track the Prime Medicine, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €527.4m. The latest transaction was disclosed on 5 August 2025 (Acquisition). Among the most active insiders: GV 2019 GP, L.L.C.. All data is openly available.
43
Insider Decl.
n/a
Thresholds
€87m
14 ops.
Buy Volume
€4m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Prime Medicine, Inc. Buy (bullish), based on 10 analysts. Average price target: US$7.12.
63Σ signal
Buys €87m€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Prime Medicine, Inc. is a biotechnology company focused on developing gene therapies to treat genetic diseases. It employs advanced technology to design innovative treatments.